Publication date: Aug 08, 2019
This post was originally published on this site Eligible Huntington’s disease patients would likely participate in a gene therapy trial regardless of the study design, but they are more inclined toward those with less invasive interventions and without a placebo group, a questionnaire-based study suggests. The results may be useful to design more patient-centered clinical trials assessing the effects of gene therapy in Huntington’s patients. With the development of new gene or molecular therapies to halt or prevent the development of Huntington’s disease – mainly administered through more invasive procedures – it is important to understand patients’ concerns and willingness to participate in these trials. Researchers at Penn designed a questionnaire to evaluate how patient clinical status, study design, and therapy goals can influence the willingness of eligible Huntington’s patients to participate in gene therapy trials. The post HD Patients Prefer Less Invasive, No-Placebo Gene Therapy Trials, Survey Says appeared first on Huntington’s Disease News.